
Eris Lifesciences shares declined by 4% after the company announced its Q3 FY25 financial results. Despite strong revenue growth, profitability took a hit due to rising expenses. As of 1:04 AM, the shares were trading 4.89% lower at Rs 1,188.60.
The company’s revenue from operations surged 49.6% year-on-year (YoY) to ₹727.45 crore, compared to ₹486.30 crore in Q3 FY24. Total income also saw a significant rise, reaching ₹731.67 crore from ₹490.50 crore in the same period last year. However, the impressive top-line growth was overshadowed by a decline in net profit, which fell 14.3% YoY to ₹86.93 crore from ₹101.46 crore.
The drop in profitability is primarily attributed to a sharp increase in total expenses, which jumped over 64% YoY to ₹615.51 crore from ₹374.63 crore. The rise in costs was driven by higher material expenses, operational costs, employee benefits, and finance expenses. Despite this, Eris Lifesciences’ profit before tax remained relatively stable at ₹116.16 crore, slightly higher than the ₹115.87 crore recorded in Q3 FY24. However, increased tax expenses further pressured the company’s net earnings.
Eris Lifesciences’ shares opened at ₹1,245.40, reaching a high of ₹1,260.40 and a low of ₹1,175.55. The stock remains volatile, with a 52-week high of ₹1,593.90 and a low of ₹809.15.
Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information.